Transfemoral Aortic Valve Implantation New Criteria to Predict Vascular Complications by Hayashida, Kentaro et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 4 , N O . 8 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 1 . 0 3 . 0 1 9Transfemoral Aortic Valve Implantation
New Criteria to Predict Vascular Complications
Kentaro Hayashida, MD, PHD, Thierry Lefèvre, MD, Bernard Chevalier, MD,
Thomas Hovasse, MD, Mauro Romano, MD, Philippe Garot, MD, Darren Mylotte, MD,
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Erik Bouvier, MD, Bertrand Cormier, MD, Marie-Claude Morice, MD
Massy, France
Objectives This study sought to evaluate the incidence, impact, and predictors of vascular compli-
cations in transcatheter aortic valve implantation (TAVI).
Background Vascular complications increase morbidity and mortality in transfemoral TAVI; however,
there remains a paucity of data describing these serious events.
Methods We performed a prospective cohort study of 130 consecutive transfemoral TAVI recipients.
Vascular complications were deﬁned by the Valve Academic Research Consortium (VARC) criteria.
The ratio of the sheath outer diameter (in millimeters) to the minimal femoral artery diameter (in
millimeters) deﬁned the sheath to femoral artery ratio (SFAR).
Results In our cohort of elderly patients (83.3  5.9 years), the logistic EuroScore was 25.8% 
11.9%. The Edwards valve was used in 102 cases (18- to 24-F) and the CoreValve in 27 (18-F). The
minimal femoral artery diameter was 8.17  1.14 mm, and the calciﬁcation (0 to 3) and tortuosity
scores (0 to 3) were 0.58  0.72 and 0.28  0.53, respectively. The mean sheath diameter was
8.10  0.82 mm, and the mean SFAR was 0.99  0.16. Vascular complications occurred in 27.6%
(VARC major: 17.3%, minor: 10.2%), and major vascular complications predicted 30-day mortality
(22.7% vs. 7.6%, p  0.049). The SFAR (hazard ratio [HR]: 186.20, 95% conﬁdence interval [CI]: 4.41
to 7,855.11), center experience (HR: 3.66, 95% CI: 1.17 to 11.49), and femoral calciﬁcation (HR: 3.44,
95% CI: 1.16 to 10.17) predicted major complications by multivariate analysis. An SFAR threshold of
1.05 (area under the curve  0.727) predicted a higher rate of VARC major complications (30.9% vs.
6.9%, p  0.001) and 30-day mortality (18.2% vs. 4.2%, p  0.016).
Conclusions Vascular complications in transfemoral TAVI are relatively frequent. VARC major vascu-
lar complications increase 30-day mortality and are predicted by experience, femoral calciﬁcation,
and SFAR. Routine application of SFAR will improve patient selection for transfemoral TAVI and may
improve outcome. (J Am Coll Cardiol Intv 2011;4:851–8) © 2011 by the American College of
Cardiology Foundation
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852Transcatheter aortic valve implantation (TAVI) has
emerged as a promising therapeutic option for patients with
severe symptomatic aortic stenosis (AS), who are ineligible
for conventional surgical aortic valve replacement (1,2).
wo transcatheter heart valves, the Edwards SAPIEN valve
Edwards Lifesciences, Irvine, California) and the Medtronic
oreValve (Medtronic, Minneapolis, Minnesota), are commer-
ially available in Europe. The Edwards valve can be
mplanted via a transfemoral or transapical approach, and
he CoreValve using a transfemoral or trans-subclavian ap-
roach. Since 2002, more than 30,000 procedures have been
erformed worldwide, and the technique is now reaching
elative maturity.
See page 859
Vascular complications are
among the most frequent and seri-
ous complications of transfemoral
TAVI, and have been associated
with significantly increased patient
morbidity and mortality (3–5). De-
spite improved patient selection and
down-sizing of the delivery system,
these complications remain the
Achilles’ heel of this novel proce-
dure. Previous studies have reported
on vascular complications in trans-
femoral TAVI (2,6–8); however,
the absence of a uniform definition
of what constitutes a major vascular
complication has made it difficult to
obtain a comprehensive picture of
these significant events. To address
this problem, the Valve Academic
Research Consortium (VARC)
have recently developed a consensus
on TAVI-related endpoints (9), including a uniform definition of
vascular complications.
The aim of this study was to describe the incidence and
clinical impact of vascular complications in a large cohort of
transfemoral TAVI patients, based on the VARC criteria,
and to identify predictors of these serious events.
Methods
Study population and design. Between October 2006 and
une 2010, consecutive high-risk patients with symptomatic
evere AS treated with TAVI at our institution were
rospectively included in our TAVI database. Patients with
ymptomatic severe AS (valve area 0.8 cm2) were consid-
red candidates for TAVI if they had a logistic European
ystem for Cardiac Operative Risk Evaluation score (Euro-
Abbreviations
and Acronyms
AS  aortic stenosis
CI  confidence interval
eGFR  estimated
glomerular filtration rate
HR  hazard ratio
MLD  minimal lumen
diameter
MSCT  multislice
computed tomography
SEIAR  sheath to external
iliac artery ratio
SFAR  sheath to femoral
artery ratio
TAVI  transcatheter aortic
valve implantation
VARC  Valve Academic
Research ConsortiumCORE)20%, or if surgery was deemed to be of excessiveisk due to significant comorbidities, or if other risk factors
ot captured by these scoring systems (e.g., porcelain aorta)
ere present. The decision to proceed with TAVI was
iscussed by a dedicated heart team, which included cardi-
logists, interventional cardiologists, anesthesiologists, car-
iac surgeons, and specialists in cardiac imaging. All pa-
ients selected for TAVI underwent screening physical
xamination, transthoracic echocardiogram, baseline labo-
atory indexes, and coronary angiography. The assessment
f the iliofemoral vessels was performed by selective ilio-
emoral angiography from 2 orthogonal planes. In addition,
creening multislice computed tomography (MSCT) of the
liofemoral vasculature was performed in patients without
ignificant renal dysfunction.
All patients agreed to participate in the study, and written
nformed consent was obtained in all cases.
Procedures. The technical aspects of the transfemoral
TAVI procedures using the Edwards valve and CoreValve
systems have been previously described in detail (10–12).
Most patients were pretreated with aspirin 160 mg and
clopidogrel 75 mg daily. If patients were not on dual
antiplatelet therapy, a loading dose of clopidogrel (300 to
600 mg) was administered. A bolus of intravenous heparin
(80 IU/kg) was administered at the beginning of the
procedure to achieve a target activated clotting time of 250
to 300 s, and the activated clotting time was measured every
30 min thereafter.
Between October 2006 and March 2008, closure of the
femoral artery access site was performed surgically (n 28).
Afterwards (n  99), we applied a “true percutaneous
pproach” using a “pre-closing technique” with the Prostar
L 10-F vascular closure system (Abbott Vascular, Abbott
ark, Illinois), which has been previously described (13,14).
n brief, direct puncture of the common femoral artery was
nsured by iliofemoral angiography from the contralateral
ide. A single Prostar device was used for 18- to 19-F
heaths and 2 devices used for 22- and 24-F sheaths. The
econd Prostar device was placed at 45° to the first one.
fter Prostar deployment, the femoral artery introducer
heath was carefully inserted over a stiff guidewire. Follow-
ng aortic valve deployment, the introducer sheath was
etracted to the external iliac artery, and angiography was
erformed to assess for iliac artery complications. The
emoral artery was subsequently closed by tying the Prostar
utures before a final iliofemoral angiogram was performed
rom the contralateral side.
Iliofemoral vascular assessment. Quantitative angiography
of the femoral, external iliac, and common iliac arteries was
performed offline after calibration with a contrast-filled
catheter. The minimal lumen diameter (MLD) of the
iliofemoral access was also measured by MSCT where
possible. Measurements and qualitative assessment were
performed by 2 independent operators. Vessel tortuosity
and calcification were evaluated as previously described (15).
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853The tortuosity score was defined as follows: 0  no
tortuosity; 1  mild tortuosity (30° to 60°); 2  moderate
tortuosity (60° to 90°); and 3  marked tortuosity (90°). The
calcification score was evaluated under fluoroscopy before
contrast injection or by MSCT, and defined as follows: 0 
no calcification; 1  mild calcification; 2  moderate
calcification; and 3  marked calcification. The Edwards
system introducer sheath outer diameters for the 24-, 22-,
19-, and 18-F sheaths are 9.2, 8.4, 7.5, and 7.2 mm, respec-
tively. The 18-F Large Check-Flo Introducer system (Cook
Medical, Bloomington, Indiana) used with the CoreValve is
7.3 mm in diameter.
Treatment of vascular complications. Treatment of vascular
complications was left to the operators’ discretion. However,
significant iliofemoral dissections and stenoses were treated
with conventional balloon angioplasty, or balloon-
expandable stents in cases where balloon angioplasty yielded
suboptimal results. Femoral perforations, insufficiently
managed with manual compression or balloon angio-
plasty, were treated with covered stents. Vessel ruptures
associated with hemodynamic instability were temporar-
ily managed with contralateral balloon occlusion while
covered stents were prepared.
Post-procedural care. All patients were observed in the
ntensive care unit for at least 24 h, with 4 hourly vascular
ssessments to detect complications. Dual antiplatelet ther-
py (aspirin 160 mg, clopidogrel 75 mg) was administered
or 3 to 6 months, and thereafter, aspirin was continued
ndefinitely. When patients required chronic anticoagula-
ion, the dose of warfarin was reduced to obtain an inter-
ational normalized ratio between 2.5 and 3.
Endpoint deﬁnitions. The primary endpoints of this study
ere vascular complications as defined by the VARC
riteria (9), and all-cause mortality (in-hospital and 30-day
ortality).
The VARC major vascular complications are defined as:
) any thoracic aortic dissection; 2) access site or access-
elated vascular injury (dissection, stenosis, perforation,
upture, arteriovenous fistula, pseudoaneurysm, hematoma,
rreversible nerve injury, or compartment syndrome) leading
o either death, significant blood transfusion (4 U),
nplanned percutaneous or surgical intervention, or irre-
ersible end organ damage; or 3) distal embolization (non-
erebral) from a vascular source requiring surgery or result-
ng in amputation or irreversible end organ damage.
The VARC minor vascular complications are defined as:
) access site or access-related vascular injury not requiring
nplanned percutaneous or surgical intervention and not
esulting in irreversible end organ damage; 2) distal embo-
ization treated with embolectomy and/or thrombectomy
nd not resulting in amputation or irreversible end organ
amage; and 3) failure of percutaneous access site closure
esulting in interventional or surgical correction and not (ssociated with death, significant blood transfusions, or
rreversible end organ damage.
The sheath to femoral artery ratio (SFAR) was defined as
he ratio between the sheath outer diameter (in millimeters)
nd the femoral artery MLD (in millimeters). The sheath to
xternal iliac artery ratio (SEIAR) was defined as the ratio
etween sheath outer diameter (in millimeters) and external
liac MLD (in millimeters). To evaluate the impact of the
earning curve, the first 50% of transfemoral TAVI proce-
ures (63 cases of 127) were defined as the “early center
xperience” group.
Statistical analysis. Quantitative variables are expressed as
mean  SD, and qualitative variables as number and
ercentage. Comparison of quantitative variables was per-
ormed with an unpaired Student t test or Wilcoxon rank
um test, depending on variable distribution. The chi-
quare test or Fisher exact test was used to compare
ualitative variables. A stepwise logistic regression analysis,
ncluding all variables with a p value 0.1 in the univariate
nalysis, was performed to determine the predictors of
ARC major vascular complications. The SFAR threshold
hat best predicted vascular complications was determined
y the intersection of the sensitivity and specificity curves.
tatistical significance was defined as p  0.05. The data
ere analyzed with PASW statistics 17.0 (SPSS Inc.,
hicago, Illinois).
esults
During the enrollment period, a total of 285 patients were
deemed eligible for TAVI by the heart team after appro-
priate screening. Of these patients, 195 (68.4%) were
identified as transfemoral TAVI candidates, and 130 un-
derwent valve implantation. A further 90 patients were
selected for nontransfemoral TAVI, due to nonfavorable
aortic or iliofemoral anatomy (aortic debris; excessively
small, tortuous, or calcified iliofemoral vessels). Of these
patients, 66 were treated by transapical TAVI and 5 by
trans-subclavian TAVI.
Thus, 130 patients underwent transfemoral TAVI using
both of the commercially available percutaneous biopros-
theses: the Edwards valve (n  102) (Cribier-Edwards,
Edwards-SAPIEN or SAPIEN XT, Edwards Life-
sciences), and the CoreValve Revalving system (n  28)
(Medtronic). In 3 patients, valve implantation was not
achieved: 1 case of recurrent ventricular fibrillation and 1
case of aortic annulus rupture after balloon valvuloplasty,
and 1 failed femoral artery access. These patients were not
included in the statistical analysis.
Patient and procedural characteristics. Patient demograph-
cs and procedural characteristics are presented in Tables 1 and 2.
he mean age was 83.3  5.9 years, with a logistic
uroScore of 25.8 11.9%, and 63% had renal dysfunctionestimated glomerular filtration rate [eGFR] 60 ml/min/
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8541.73 m2). The femoral artery MLD was 8.17  1.14 mm,
nd the mean sheath outer diameter was 8.10  0.82 mm,
iving an SFAR of 0.994  0.155 (Fig. 1). The distribu-
ions of femoral artery calcification and tortuosity scores are
hown in Online Figure 1.
Vascular complications. Vascular complications were ob-
served in 35 patients (27.6%), and included 22 (17.3%)
VARC major complications and 13 (10.2%) VARC minor
complications (Table 3).
Major femoral complications (n  11 [8.7%]) included 1
vessel rupture, 6 dissections, and 3 stenosis/occlusions, and
major iliac complications (n  13 [10.3%]) consisted of 6
ruptures and 7 dissections. These serious complications
were treated with balloon angioplasty alone (n  2 [1.5%]),
femoral stenting (n  3 [2.4%]), iliac stenting (n  5
[3.9%]), thoracic aortic stenting (n  1 [0.8%]), and
emergent surgical repair (n  8 [6.3%]). Blood transfusion
(4 U) was required in 5 cases, including 1 aortic and 4 iliac
artery ruptures. Femoral access site infections occurred in 3
patients who underwent surgical femoral artery closure.
These 3 patients were diabetic, had impaired renal function,
and were treated early in our center’s experience in a cardiac
catheterization suite.
VARC minor complications (n  13) included 1 access
site hematoma, 1 femoral artery pseudoaneurysm, and 11
Prostar failures that resulted in bleeding (n  8) or femoral
artery occlusion (n  3). These complications were treated
Table 1. Baseline Characteristics of the Study Population (N  127)
Age, yrs 83.3 5.9
Female 65 (51.2%)
BMI, kg/m2 25.3 4.1
Diabetes 29 (22.8%)
Hyperlipidemia 54 (42.5%)
Hypertension 92 (72.4%)
Current smoker 5 (3.9%)
NYHA functional class III or IV 113 (89.0%)
Coronary artery disease 80 (63.0%)
Previous MI 13 (10.2%)
Previous PCI 45 (35.4%)
Previous CABG 20 (15.7%)
Cerebrovascular disease 19 (15.0%)
COPD 43 (33.9%)
eGFR, ml/min/1.73 m2 50.4 23.6
eGFR 60 ml/min/1.73 m2 80 (63.0%)
Logistic EuroScore, % 25.8 11.9
Pulmonary hypertension 42 (33.1%)
LVEF, % 48.1 14.1
LVEF 40% 45 (35.4%)
Values are mean SD or n (%).
BMI  body mass index; CABG  coronary artery bypass graft; COPD  chronic obstructive
pulmonary disease; eGFR estimated glomerular filtration rate; LVEF left ventricular ejection
fraction; MI myocardial infarction; NYHA  New York Heart Association; PCI  percutaneous
coronary intervention.with balloon angioplasty (n  3) or femoral artery stenting(n  5). In contrast to the femoral artery, all iliac artery
complications are classified as VARC major complications.
Vascular complications and death. Death at 30 days oc-
curred in 13 of 127 (10.2%) patients. Five died due to
vascular complications (Table 4). Aortic rupture (n  1),
iliac rupture (n  2), iliac dissection (n  1), and femoral
Figure 1. The Distribution of SFAR
The histogram of the sheath to femoral artery ratio (SFAR) showed a
Table 2. Procedural Characteristics of the Study Population (N  127)
Edwards SAPIEN valve 100 (78.7%)
CoreValve 27 (21.3%)
General anesthesia 66 (52.0%)
Percutaneous femoral artery closure 99 (78.0%)
Sheath size, F 20.8 2.5
18 42 (33.1%)
19 16 (12.6%)
22 37 (29.1%)
24 32 (25.2%)
Introducer sheath diameter, mm 8.10 0.82
Femoral artery MLD, mm 8.17 1.14
SFAR 0.99 0.16
Femoral artery calciﬁcation score (0–3) 0.58 0.72
Femoral artery tortuosity score (0–3) 0.28 0.53
Common iliac artery MLD, mm 10.3 2.43
External iliac artery MLD, mm 8.73 1.60
SEIAR 0.98 0.33
Iliac artery calciﬁcation score (0–3) 0.96 0.83
Iliac artery tortuosity score (0–3) 0.84 0.75
Values are n (%) or mean SD.
MLDminimal lumendiameter; SEIAR sheath to external iliac artery ratio; SFAR sheath to
femoral artery ratio.normal distribution.
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855artery access site infection (n  1) were directly responsible
or these deaths.
Predictors of VARC major vascular complications and outcomes.
The SFAR (hazard ratio [HR]: 186.20, 95% confidence
interval [CI]: 4.41 to 7,855.11, p  0.006), early center
experience (HR: 3.66, 95% CI: 1.17 to 11.49, p  0.023),
and femoral artery calcium score (HR: 3.44, 95% CI: 1.16 to
10.17, p  0.026) were identified as independent predictors
Table 3. Vascular Complications
All Patients
(N  127)
VARC Major
Complications
VARC Minor
Complications
Patients with vascular
complications
35 (27.6%) 22 (17.3%) 13 (10.2%)
Femoral artery 24 (18.9%) 11 (8.7%) 13 (10.2%)
Rupture 1 (0.8%) 1 (0.8%) 0
Dissection 6 (4.7%) 6 (4.7%) 0
Stenosis/occlusion 3 (2.4%) 3 (2.4%) 0
Pseudoaneurysm 2 (1.6%) 1 (0.8%) 1 (0.8%)
Hematoma 1 (0.8%) 0 1 (0.8%)
Prostar failure 11 (8.7%) 0 11 (8.7%)
Death 1 (0.8%) 1 (0.8%) 0
Iliac artery 13 (10.2%) 13 (10.2%) 0
Rupture 6 (4.7%) 6 (4.7%) 0
Dissection 7 (5.5%) 7 (5.5%) 0
Death 3 (2.4%) 3 (2.4%) 0
Aorta 1 (0.8%) 1 (0.8%) 0
Rupture 1 (0.8%) 1 (0.8%) 0
Death 1 (0.8%) 1 (0.8%) 0
Blood transfusion 8 (6.2%) 7 (7.9%) 1 (0.8%)
Local infection 3 (2.4%) 3 (2.4%) 0
Vascular intervention 27 (21.3%) 19 (15.0%) 8 (6.3%)
Balloon angioplasty 5 (3.9%) 2 (1.5%) 3 (2.4%)
Femoral stenting 8 (6.3%) 3 (2.4%) 5 (3.9%)
Iliac stenting 5 (3.9%) 5 (3.9%) 0
Aortic stenting 1 (0.8%) 1 (0.8%) 0
Emergent vascular surgery 8 (6.3%) 8 (6.3%) 0
Hospital stay (days) 11.0 7.9 16.5 11.6 9.83 4.04
In-hospital mortality 16 (12.6%) 6 (4.7%) 10 (7.9%)
30-day mortality 13 (10.2%) 5 (3.9%) 6 (4.7%)
Values are n (%) or mean SD.
VARC Valve Academic Research Consortium.
Table 4. Description of Death Due to Vascular Complications
Patient #
No. in
Cohort Age, yrs Sex Vascular Access
Sheath
Size, F SFAR
1 17 84 M Surgical 24 1.18 Il
2 24 89 M Surgical 24 1.21 F
3 30 70 F Surgical 24 1.03 Il
4 109 84 M Percutaneous 24 1.10 Il
5 166 86 M Percutaneous 18 0.74 TF female; Mmale; SFAR sheath to femoral artery ratio.of VARC major vascular complications by multivariate
analysis (Table 5). The SEIAR did not predict vascular
omplications, and although the diameter of the intro-
ucer sheath predicted major vascular complications in
he univariate analysis (8.7  0.5 mm vs. 8.0  0.9 mm,
 0.010), it was no longer significant after adjustment
or other variables (p  0.157). The type of TAVI was
ignificantly associated with vascular complications in
nivariate analysis, with significantly fewer complications
n the CoreValve cohort compared with the Edwards
alve cohort (p  0.004). However, the type of device was
Complication Treatment
Survival,
Days Cause of Death
lusion Surgery 6 Multiple organ failure
l access site infection Surgery 27 Sepsis, multiple organ failure
ture Surgery 3 Multiple organ failure
ture Surgery 0 Hemorrhagic shock
c aorta rupture Covered stent 0 Hemorrhagic shock
Table 5. Univariate and Multivariate Analysis of the Clinical and
Procedural Characteristics According to the Incidence of
VARC Major Vascular Complications
Multivariate
Variable
Univariate
p Value p Value
Odds
Ratio 95% CI
Age, yrs 0.069 0.860
Female 0.937
BMI, kg/m2 0.850
Diabetes 0.575
eGFR 60 ml/min/1.73 m2 0.222
Logistic EuroScore, % 0.228
LVEF 40% 0.212
Chronic anticoagulation 0.870
Activated clotting time, s 0.710
TAVI type 0.004 0.057
Early center experience 0.007 0.023 3.66 1.17–11.49
Sheath outer diameter, mm 0.010 0.157
Femoral artery MLD, mm 0.797
SFAR 0.001 0.006 186.20 4.41–7,855.11
Femoral artery calciﬁcation (0–3) 0.023 0.026 3.44 1.16–10.17
Femoral artery tortuosity (0–3) 0.709
Common iliac MLD, mm 0.419
External iliac MLD, mm 0.264
SEIAR 0.577
Iliac artery calciﬁcation (0–3) 0.077
Iliac artery tortuosity (0–3) 0.459
Three cases were excluded because of death before valve deployment and access closure.
TAVI transcatheter aortic valve implantation; other abbreviation as in Tables 1, 2, and 3.iac occ
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856no longer predictive of vascular complications when
adjusted for other variables in the multivariate model
(p  0.057). It is likely that the strong association
etween the type of TAVI with both SFAR (p  0.001)
nd center experience (p  0.001) are responsible for this
esult.
Increased rates of in-hospital mortality (27.3% vs. 9.5%,
 0.023), 30-day mortality (22.7% vs. 7.6%, p  0.049),
nd longer hospital stay (16.5  11.6 days vs. 9.7  6.2
ays, p  0.016) were observed in patients with VARC
ajor complications. VARC minor complications were not
ssociated with increased 30-day mortality (7.7% vs. 13.2%,
 0.574) or increased duration of hospital stay (9.8  4.0
ays vs. 11.0  8.3 days, p  0.636).
SFAR threshold predicts VARC major vascular complications.
The sensitivity–specificity curves identified a threshold
SFAR of 1.05, which predicted VARC major vascular
complications (Fig. 2). With this cut point, the sensitiv-
ity, specificity, and positive and negative predictive values
were 66.7%, 65.6%, 40.7%, and 84.7%, respectively, and
the area under the receiver-operator characteristic curve
was 0.727. Using this SFAR threshold, the minimal
femoral artery diameter necessary for the 19- and 18-F
introducer sheaths was calculated as 7.1 and 6.9 mm,
respectively.
In noncalcified iliofemoral vessels (calcium score  0),
the SFAR increased to 1.10 and, conversely, decreased to
1.00 in calcified arteries (calcium score 1 to 3). Using this
SFAR threshold, the minimal femoral artery diameter
Figure 2. SFAR Threshold Predicts VARC Major Vascular Complications
The sensitivity and speciﬁcity curve identiﬁed the threshold sheath femoral
artery ratio (SFAR) of 1.05 as predictive of VARC major vascular complica-
tions. Solid line  sensitivity; broken line  speciﬁcity. VARC  Valvet
Academic Research Consortium.necessary for the 19- and 18-F introducer sheaths was
calculated as 6.8 and 6.5 mm, respectively, in noncalcified
iliofemoral vessels, and 7.5 and 7.2 mm, respectively, in
calcified iliofemoral vessels.
Clinical outcomes according to SFAR. Clinical outcomes
were compared according to the SFAR cut point of 1.05
(Table 6). This cut point predicted higher rates of VARC
major complications (30.9% vs. 5.6%, p  0.001). An
SFAR 1.05 was also associated with an increased inci-
dence of 30-day mortality (18.2% vs. 2.8%, p  0.004).
Discussion
This study provides the first detailed description of vascular
complications, as defined by the VARC criteria (10), in a
large cohort of patients treated by transfemoral TAVI. Our
results demonstrate that VARC major vascular complica-
tions predict both 30-day and in-hospital mortality. In
contrast, VARC minor complications are not associated
with increased mortality. Furthermore, we have described
the SFAR, a novel tool which predicts VARC major
vascular complications, and is strongly associated with
clinical outcomes, including mortality.
Uniform deﬁnition of vascular complications with TAVI. To
ate, vascular complications have been described in 8% to
0.7% of Edwards valve recipients (1–3,6,8,16,17), and
.9% to 16% of CoreValve patients (5–7,18). The consid-
rable variation in the reported incidence of these compli-
ations arises, in part, from the absence of a standardized
efinition for vascular complications in TAVI (1–3,5–8,
6–18). Most studies on TAVI have only reported compli-
ations that required further percutaneous or surgical inter-
ention (6,16), and thus, the true frequency of vascular
omplications in transfemoral TAVI may have been under-
stimated. In an effort to standardize the reporting of TAVI
ata, the VARC have recently developed a consensus on
AVI-related endpoints (9), including a uniform definition
f vascular complications. In our series of mixed implant
Table 6. Comparison of the Clinical Outcomes According to
SFAR Threshold
SFAR
Variables >1.05 (n  55) <1.05 (n  72) p Value
Any vascular complication 23 (41.8%) 12 (16.7%) <0.001
VARC Major 17 (30.9%) 5 (6.9%) 0.001
VARC Minor 6 (10.9%) 7 (9.7%) 0.827
Femoral artery complication 15 (27.3%) 9 (12.5%) 0.035
Iliac artery complication 11 (20.0%) 2 (2.8%) 0.002
In-hospital mortality 11 (20.0%) 5 (6.9%) 0.033
30-day mortality 10 (18.2%) 3 (4.2%) 0.016
Values are n (%). p Values in bold are statistically significant.
Abbreviations as in Tables 2 and 3.ransfemoral TAVI patients, we defined vascular complica-
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857tions according to the VARC criteria, and observed a
complication rate of 27.6%, higher than previously de-
scribed. The rate of major complications in our study was
17.3%, and is comparable to other published series (1,3,8,18);
however, the overall rate of complications was amplified by the
addition of VARC minor complications (10.2%). Although
the routine application of the VARC criteria for vascular
complications will provide reliable, standardized information
for TAVI-related research, it is likely to increase the reported
rates of complications despite ever-improving operator exper-
tise and device safety.
Impact of vascular complications on mortality. The impor-
tance of vascular complications in transfemoral TAVI pa-
tients remains unclear (6,8,17). Two small series of Edwards
valve (n  54) (8) and mixed Edwards and CoreValve
patients (n  45) (6), and a large international registry (n 
463) of Edwards valve patients (17), found no association
between vascular complications and mortality. In contrast,
in a multicenter cohort of 168 Edwards valve recipients,
major vascular complications occurred in 13% of cases and
were associated with a mortality rate of 25% (3). In our
study, VARC major vascular complications were associated
with both in-hospital (27.3% vs. 9.5%, p  0.023) and
30-day mortality (22.7% vs. 7.6%, p  0.049). Consistent
with previous reports (3), VARC major vascular complica-
tions were associated with a 3-fold increase in the relative
risk of death. VARC minor complications were not associ-
ated with mortality. The reason for the contrasting reports
on the association vascular complications with patient mor-
tality is not known, but may be related to the definition of
vascular complications used. The VARC criteria includes
factors such as blood transfusion (4 U) and ischemia-
related end organ damage, which may not have been
considered vascular complications in previous reports, but
nonetheless portend a poor prognosis and thus enhance the
association of vascular complications and mortality. For
example, the patient in our cohort who developed a wound
infection with subsequent septicemia, multiorgan failure,
and ultimately death would not have been classified as a
major vascular complication in previous studies. The VARC
criteria may therefore represent a more inclusive, represen-
tative definition of vascular complications; however, further
studies are required to investigate the relationship between
VARC major complications and mortality.
SFAR predicts vascular complications and mortality. There is
need to identify predictors of vascular complications,
hough to our knowledge, we are the first to report predic-
ors of vascular complications in transfemoral TAVI. Fem-
ral artery calcification and increasing diameter of the
ntroducer sheath have been previously identified as inde-
endent predictors of major vascular complications in en-
ovascular aortic aneurysm repair (13,19,20); however, there
s a paucity of data on the predictors of these complications
n TAVI patients. Our study identified femoral arteryalcification and center experience to be predictive of
ascular complications in transfemoral TAVI. Indeed, the
OURCE registry observed that the incidence of vascular
omplications decreased with improved center experience
17). In our study, the introducer sheath outer diameter
redicted vascular complications in the univariate analysis;
owever, it was not predictive of vascular complications
ollowing adjustment for other variables. In contrast, the
trongest predictor of major vascular complications was the
FAR. This novel index reflects both femoral artery diam-
ter and size of the introducer sheath, and was a more
owerful predictor of vascular events than either of these
riteria taken in isolation. When the femoral artery calcium
core and SFAR were combined, the minimal femoral artery
iameter required for the 19- and 18-F introducer sheaths
as calculated as 6.8 and 6.5 mm, respectively, in noncal-
ified iliofemoral vessels, and 7.5 and 7.2 mm, respectively,
n calcified iliofemoral vessels. Although these measure-
ents represent more restrictive criteria than previously
ecommended (6,8,15,17), we believe that they offer the best
hance of avoiding serious iliofemoral complications, par-
icularly during the initial learning curve. Alternative ap-
roaches (transapical, transaortic, trans-subclavian, or ret-
operitoneal) should be considered in patients with
orderline femoral artery diameters (6.0 to 6.5 mm) follow-
ng careful vascular screening with selective iliofemoral
ngiography, or if possible, MSCT. We believe that the
outine application of SFAR will improve patient selection
or transfemoral TAVI, reduce vascular complications, and
ltimately, improve patient outcome.
Study limitations. Our study reports on a single-center,
transfemoral TAVI cohort of limited size, recruited during
our initial experience with this new technology. Neverthe-
less, our sample size is comparable to previous reports (6,8),
and we believe it is important to describe the serious
complications that may arise during the learning curve in a
real-world experience. We opted to include patients who
received the 22- and 24-F Edwards sheaths, which are no
longer commercially available in Europe, as they were part
of our initial experience and because the SFAR takes into
account the size of the introducer sheath. Assessment of the
iliofemoral vasculature with MSCT was not performed in
all patients (n  58), due to the high prevalence of renal
dysfunction in our cohort; however, our study reflects
real-world practice where the iliofemoral vessels are fre-
quently assessed by conventional angiography. In the cur-
rent paper, we report only in-hospital and 30-day outcomes.
Longer-term follow-up, particularly in patients with vascu-
lar complications, is of significant interest and will be
reported in due course.
Further studies of larger patient populations are required
to confirm our results.
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858Conclusions
Vascular complications in transfemoral TAVI remain a
significant issue despite improving center experience and
smaller delivery systems. VARC major vascular complica-
tions occurred in 17.3% of patients in this series and were
associated with increased 30-day mortality. VARC major
complications are predicted by the SFAR, femoral artery
calcification, and center experience. Routine application of
the SFAR, with a cutoff value of 1.05, may improve
TAVI-related outcomes.
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